Arena Pharmaceuticals, Inc. (ARNA)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.62-0.06 (-3.57%)
As of 3:33 PM EDT. Market open.
People also watch:
VVUSOREXARIAKERXAMRN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.68
Prev Close1.68
Bid1.59 x 13400
Ask1.60 x 6100
Day's Range1.59 - 1.70
52wk Range1.30 - 2.99
1y Target EstN/A
Market Cap394.07M
P/E Ratio (ttm)-3.68
Beta1.52
Volume871,403
Avg Vol (3m)1,464,390
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cubeyesterday

    ETF’s with exposure to Arena Pharmaceuticals, Inc. : August 23, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Arena Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to ARNA-US. Comparing the performance and risk of Arena Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire9 days ago

    Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer

    "I am excited to have Vince join us at Arena," said Mr. Munshi. Mr. Aurentz joins Arena with over 27 years of experience in the pharmaceutical and biotech industry. Prior to Arena, Mr. Aurentz served as the Chief Business Officer of Epirus Biopharmaceuticals.

  • Capital Cube13 days ago

    ETF’s with exposure to Arena Pharmaceuticals, Inc. : August 11, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Arena Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to ARNA-US. Comparing the performance and risk of Arena Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)